Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting

被引:1
|
作者
Mannelli, Paolo [1 ]
Douaihy, Antoine B. [2 ]
Akerman, Sarah C. [3 ]
Legedza, Anna [3 ]
Fratantonio, James [3 ]
Zavod, Abigail [3 ]
Sullivan, Maria A. [3 ,4 ]
机构
[1] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, 3074,2213 Elba St,Ste 156, Durham, NC 27705 USA
[2] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA
[3] Alkermes Inc, Waltham, MA USA
[4] Columbia Univ, Dept Psychiat, New York, NY USA
来源
AMERICAN JOURNAL ON ADDICTIONS | 2022年 / 31卷 / 02期
关键词
D O I
10.1111/ajad.13264
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background and Objectives Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient-centered approach. To better support patient autonomy in the decision-making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended-release naltrexone (XR-NTX). Methods The posthoc analysis included adults with OUD currently receiving BUP (<= 8 mg/day) and seeking transition to XR-NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR-NTX and for choosing BUP. Results The most common reasons for initiating a transition to XR-NTX were "Seeking to be opioid-free" (63.4%) and "Tired of daily pill taking" (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR-NTX as a treatment option when initiating BUP (78.2%). Discussions and Conclusions Patients' reasons for seeking XR-NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes. Scientific Significance These findings may assist clinicians in optimizing outcomes of the BUP to XR-NTX transition and supporting patients to make better informed MOUD decisions.
引用
收藏
页码:142 / 147
页数:6
相关论文
共 50 条
  • [31] Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial
    Bisaga, Adam
    Mannelli, Paolo
    Yu, Miao
    Nangia, Narinder
    Graham, Christine E.
    Tompkins, D. Andrew
    Kosten, Thomas R.
    Akerman, Sarah C.
    Silverman, Bernard L.
    Sullivan, Maria A.
    DRUG AND ALCOHOL DEPENDENCE, 2018, 187 : 171 - 178
  • [32] Extending the Youth Opioid Recovery Support (YORS) Intervention With Patient Choice of Extended-Release Naltrexone or Extended-Release Buprenorphine
    Fishman, Marc
    Selby, Victoria
    Wildberger, Jared
    Lavorato, Luciana
    Thomas, Julia
    Moody, Stanley
    Stidham, Jennifer
    AMERICAN JOURNAL ON ADDICTIONS, 2021, 30 (03): : 261 - 262
  • [33] Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial
    Levin, Frances R.
    Mariani, John J.
    Pavlicova, Martina
    Choi, C. Jean
    Basaraba, Cale
    Mahony, Amy L.
    Brooks, Daniel J.
    Naqvi, Nasir
    Bisaga, Adam
    DRUG AND ALCOHOL DEPENDENCE, 2021, 219
  • [34] Comparing outcomes of extended-release naltrexone in adolescents and young adults with opioid use disorder
    Mitchell, Shannon Gwin
    Fletcher, Jesse B.
    Monico, Laura B.
    Gryczynski, Jan
    Fishman, Marc J.
    O'Grady, Kevin E.
    Schwartz, Robert P.
    JOURNAL OF SUBSTANCE USE & ADDICTION TREATMENT, 2024, 163
  • [35] Optimizing opioid use disorder treatment with naltrexone or buprenorphine
    Rudolph, Kara E.
    Diaz, Ivan
    Luo, Sean X.
    Rotrosen, John
    Nunes, Edward, V
    DRUG AND ALCOHOL DEPENDENCE, 2021, 228
  • [36] Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
    Marcus, Ruthanne
    Makarenko, Iuliia
    Mazhnaya, Alyona
    Zelenev, Alexei
    Polonsky, Maxim
    Madden, Lynn
    Filippovych, Sergii
    Dvoriak, Sergii
    Springer, Sandra A.
    Altice, Frederick L.
    DRUG AND ALCOHOL DEPENDENCE, 2017, 179 : 213 - 219
  • [37] Do patient characteristics moderate the effect of extended-release naltrexone (XR-NTX) for opioid use disorder?
    Friedmann, Peter D.
    Wilson, Donna
    Nunes, Edward V.
    Hoskinson, Randall, Jr.
    Lee, Joshua D.
    Gordon, Michael
    Murphy, Sean M.
    Bonnie, Richard J.
    Chen, Donna T.
    Boney, Tamara Y.
    O'Brien, Charles P.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 85 : 61 - 65
  • [38] Extended-release naltrexone overlooked in opioid use disorders guideline
    Rieb, Launette M.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2018, 190 (28) : E862 - E862
  • [39] A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail
    Gordon, Michael S.
    Mitchell, Shannon Gwin
    Blue, Thomas R.
    Vocci, Frank J.
    Fishman, Marc J.
    Murphy, Sean M.
    Couvillion, Kathy
    Maher, Kelly
    Ryan, Danielle
    Wenzel, Kevin
    Danner, Martha L.
    Jarvis, Daniel K.
    JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2021, 128
  • [40] EFFICACY OF EXTENDED-RELEASE INJECTABLE BUPRENORPHINE FOR PATIENTS WITH DUAL OPIOID AND COCAINE USE DISORDER
    Marsden, John
    Kelleher, Michael
    DRUG AND ALCOHOL DEPENDENCE, 2024, 260